Press Release / Media Release
Please find enclosed the press release on the financial performance of the Company for the Quarter and nine-months ended 31st December, 2017 with the title - 'Morepen Labs boards the growth ladder with the peer group in the healthcare and pharmaceutical sector'. Kindly acknowledge the receipt and take it on your record. Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December, 2017
This is to inform you that the Board of Directors of the Company, in their meeting held on Monday, 22nd January, 2018 (Timings: Meeting commenced at 8.30 a.m. and concluded at 9.22 a.m.), have inter-alia considered and approved the Standalone Un-audited Financial Results of the Company for the Quarter and nine-months ended 31st December, 2017, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.... Outcome of Board Meeting
This is to inform you that the Board of Directors of the Company, in their meeting held on Monday, 22nd January, 2018 (Timings: Meeting commenced at 8.30 a.m. and concluded at 9.22 a.m.), have inter-alia considered and approved the Standalone Un-audited Financial Results of the Company for the Quarter and nine-months ended 31st December, 2017, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.... Shareholding for the Period Ended December 31, 2017
Morepen Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Statement Of Investor Compliant For The Quarter Ended 31St December 2017
Please find attached herewith Statement of Investors complaints under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended December 31, 2017 Notice Of Board Meeting On Monday, 22Nd January, 2018 And Intimation Of Closure Of Trading Window
Dear Sir, Notice is hereby given, pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of Board of Directors of the Company is scheduled to be held on Monday, 22nd January, 2018, inter-alia, to consider, approve and take on record the Un-audited Financial Results of the Company for the quarter and nine months ended 31st December, 2017.... Morepen Laboratories Limited
The United States Food and Drug Administration (US FDA) has cleared Montelukast Sodium, a bulk drug/ API manufactured by Morepen Laboratories, for sale in the US market. This gives Morepen an entry... Press Release / Media Release
Dear Sir, Please find enclosed the press release on 'Morepen gets US FDA clearance for its bulk drug Montelukast Sodium'. Kindly acknowledge the receipt and take it on your record. Morepen Labs net profit up by 24% to Rs.10.37 crore in Q2
Morepen Laboratories Ltd., a Rs.600 crore pharmaceutical and healthcare products major, has reported a stable set of numbers in the second quarter of fiscal 201718. The company has registered a 24 per cent jump in its Press Release / Media Release
Dear Sir, Please find enclosed the press release on the financial performance of the Company for the Quarter and Half-year ended 30th September, 2017. Kindly acknowledge the receipt and take it on your record.